Inge J M Willemstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Inge J M Willemstein has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Janneke C M Heijne
Public Health Service of Amsterdam, Amsterdam, The Netherlands
2 shared publications- A. M. Żakowicz
AIDS Healthcare Foundation (AHF) Europe, Amsterdam, the Netherlands
1 shared publication Birgit H B van Benthem
Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands
1 shared publication- Birgit H. B. van Benthem
Centre for infectious disease control, National institute for public health and the environment (RIVM), Bilthoven, the Netherlands
1 shared publication - Daphne Amanda van Wees
Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands
1 shared publication Eddymurphy Akwiwu
1 shared publication
Latest Publications
- Open Access
- 13 August 2026
- Published by Elsevier in SSRN Electronic Journal
Increased HIV Incidence during Event-Driven PrEP Compared to Daily PrEP in the Netherlands
Background: Clinical trials demonstrated high efficacy of daily and event-driven oral pre-exposure prophylaxis (PrEP) in HIV prevention. Event-driven PrEP involves taking two tablets before and two times one tablet after sexual contact (2-1-1/on-demand). While both are implemented in Dutch clinical practice, evaluating real-world effectiveness requires large-scale data from routine clinical care. This study compared HIV incidence between daily and event-driven PrEP in the Netherlands.Methods: We used surveillance data from the Dutch national PrEP program (August 1, 2019-December 31, 2025). Individuals ≥16 years with ≥1 follow-up consultation after PrEP initiation were included; PrEP regimen since last visit was recorded at each visit. Person-time was modeled as time-varying based on the regimen reported at each consultation. HIV incidence rates were calculated per 100 person-years and Cox proportional hazards models estimated hazard ratios between regimens for HIV acquisition, adjusted for sociodemographics, sexual behavior, and history of sexually transmissible infections.Findings: 16,469 individuals (15,843 men who have sex with men, 579 transgender and gender diverse persons, 45 women and two men who have sex with women) initiated PrEP and had ≥1 follow-up visit (median follow-up 2·0 years (IQR=0·8-4·0)). Median age was 33 years (IQR=27-44). 49 PrEP users were diagnosed with HIV over 41,092 person-years (IR=0·12/100 py;95%CI=0·09-0·16), of whom 42 event-driven users (IR=0·20/100 py;95%CI=0·15-0·27) and seven daily PrEP users (IR=0·04/100 py;95%CI=0·02-0·07). In multivariable Cox regression, event-driven PrEP use was associated with a higher hazard of HIV acquisition (aHR=7·0;95%CI=3·0-16·4).Interpretation: Despite overall low HIV incidence, the incidence rate in the Dutch national PrEP program was seven-fold higher during event-driven PrEP use compared to daily, which may be due to lower adherence. These findings denotes that, in real-world settings, improved person-centered counseling is needed for individuals interested in, or using event-driven PrEP. Research should identify domains and preferred methods of support.
- 13 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessIncreased HIV Incidence during Event-Driven PrEP Compared to Daily PrEP in the Netherlands
Background: Clinical trials demonstrated high efficacy of daily and event-driven oral pre-exposure prophylaxis (PrEP) in HIV prevention. Event-driven PrEP involves taking two tablets before and two times one tablet after sexual contact (2-1-1/on-demand). While both are implemented in Dutch clinical practice, evaluating real-world effectiveness requires large-scale data from routine clinical care. This study compared HIV incidence between daily and event-driven PrEP in the Netherlands.Methods: We used surveillance data from the Dutch national PrEP program (August 1, 2019-December 31, 2025). Individuals ≥16 years with ≥1 follow-up consultation after PrEP initiation were included; PrEP regimen since last visit was recorded at each visit. Person-time was modeled as time-varying based on the regimen reported at each consultation. HIV incidence rates were calculated per 100 person-years and Cox proportional hazards models estimated hazard ratios between regimens for HIV acquisition, adjusted for sociodemographics, sexual behavior, and history of sexually transmissible infections.Findings: 16,469 individuals (15,843 men who have sex with men, 579 transgender and gender diverse persons, 45 women and two men who have sex with women) initiated PrEP and had ≥1 follow-up visit (median follow-up 2·0 years (IQR=0·8-4·0)). Median age was 33 years (IQR=27-44). 49 PrEP users were diagnosed with HIV over 41,092 person-years (IR=0·12/100 py;95%CI=0·09-0·16), of whom 42 event-driven users (IR=0·20/100 py;95%CI=0·15-0·27) and seven daily PrEP users (IR=0·04/100 py;95%CI=0·02-0·07). In multivariable Cox regression, event-driven PrEP use was associated with a higher hazard of HIV acquisition (aHR=7·0;95%CI=3·0-16·4).Interpretation: Despite overall low HIV incidence, the incidence rate in the Dutch national PrEP program was seven-fold higher during event-driven PrEP use compared to daily, which may be due to lower adherence. These findings denotes that, in real-world settings, improved person-centered counseling is needed for individuals interested in, or using event-driven PrEP. Research should identify domains and preferred methods of support.
- Open Access
- 25 June 2026
- Published by BMJ in Sexually Transmitted Infections
National prevalence estimates of chlamydia and gonorrhoea in the Netherlands (PECAN): comparison of two national cross-sectional surveys
Objectives: National prevalence estimates of chlamydia and gonorrhoea are essential to inform public health strategies and support evidence-based policy development. The aim was to generate national prevalence chlamydia and gonorrhoea estimates in 2022/2023, identify associated risk factors and compare prevalence over time. Methods: Five years after the first survey in 2016/2017, a second national cross-sectional probability sample survey about sexual health among men and women aged 16–34 years in the Netherlands was conducted between October 2022 and March 2023. Sexually active survey participants were invited to participate in the prevalence study and received a home-based sampling kit. Returned samples were tested for chlamydia and gonorrhoea in a laboratory (ie, nucleic acid amplification test). Weighting techniques were used to correct for selective non-response. Multivariable logistic regression analyses were performed to identify risk factors of infection. Results: Of 6277 survey participants invited for the prevalence study, 1142 (18.2%) returned a specimen. The weighted overall chlamydia prevalence was 3.5% (95% CI 2.3% to 5.4%), and prevalence was higher in younger age groups (<25 vs ≥25 years). Due to low numbers in other groups, risk factor analysis was only possible among women aged 18–24 years, where risk factors for chlamydia included being <20 years, vocational education, no steady relationship and condomless sex. As in 2016/2017, no gonorrhoea cases were detected in 2022/2023. Chlamydia prevalence and associated risk factors did not change, except for higher prevalence among university-educated individuals in 2022/2023. Discussion: Chlamydia prevalence among young sexually active men and women in the Netherlands remained stable between 2016/2017 and 2022/2023, with higher prevalence observed in younger age groups in both studies. Given recent changes in chlamydia testing guidelines in the Netherlands towards more restrictive testing of asymptomatic individuals, probability sample surveys with laboratory-confirmed STI testing are crucial for monitoring prevalence trends and evaluating public health policy.
- 25 June 2026
- Published by BMJ in Sexually Transmitted Infections
Open AccessNational prevalence estimates of chlamydia and gonorrhoea in the Netherlands (PECAN): comparison of two national cross-sectional surveys
Objectives: National prevalence estimates of chlamydia and gonorrhoea are essential to inform public health strategies and support evidence-based policy development. The aim was to generate national prevalence chlamydia and gonorrhoea estimates in 2022/2023, identify associated risk factors and compare prevalence over time. Methods: Five years after the first survey in 2016/2017, a second national cross-sectional probability sample survey about sexual health among men and women aged 16–34 years in the Netherlands was conducted between October 2022 and March 2023. Sexually active survey participants were invited to participate in the prevalence study and received a home-based sampling kit. Returned samples were tested for chlamydia and gonorrhoea in a laboratory (ie, nucleic acid amplification test). Weighting techniques were used to correct for selective non-response. Multivariable logistic regression analyses were performed to identify risk factors of infection. Results: Of 6277 survey participants invited for the prevalence study, 1142 (18.2%) returned a specimen. The weighted overall chlamydia prevalence was 3.5% (95% CI 2.3% to 5.4%), and prevalence was higher in younger age groups (<25 vs ≥25 years). Due to low numbers in other groups, risk factor analysis was only possible among women aged 18–24 years, where risk factors for chlamydia included being <20 years, vocational education, no steady relationship and condomless sex. As in 2016/2017, no gonorrhoea cases were detected in 2022/2023. Chlamydia prevalence and associated risk factors did not change, except for higher prevalence among university-educated individuals in 2022/2023. Discussion: Chlamydia prevalence among young sexually active men and women in the Netherlands remained stable between 2016/2017 and 2022/2023, with higher prevalence observed in younger age groups in both studies. Given recent changes in chlamydia testing guidelines in the Netherlands towards more restrictive testing of asymptomatic individuals, probability sample surveys with laboratory-confirmed STI testing are crucial for monitoring prevalence trends and evaluating public health policy.
- Open Access
- 25 January 2025
- Published by Springer Nature in BMC Health Services Research
- Vol. 25 (1) , 1-11
Self-sampling and self-testing for HIV at a commercial and community-based test provider in the Netherlands: user preferences and usability
HIV self-sampling and -testing (HIVSS/ST) reduces testing barriers and potentially reaches populations who may not test otherwise. In the Netherlands, at-home HIV tests became commercially available around 2016, but data on user experiences are limited. This study aimed to explore characteristics of users and their experiences with HIVSS/ST. In 2022 and 2023, a survey was distributed among users of one online commercial provider and one community-based provider; either users ordered a commercial online HIVSS/ST or they sought a free-of-charge HIVST via the community-based provider. Questions included usability, preferences, and barriers of HIVSS/ST-testing. We compared characteristics and experiences of users between providers, risk groups and first-time and repeat testers. In total, 133 users completed the survey; 89 (67%) via the commercial provider and 44 (33%) via the community-based provider. Response rates per provider were 2% and 26%, respectively. Users who bought their test at the commercial provider were more often Gay and Bisexual Men (GBM) (42%), 35 + years (43%), and born in the Netherlands (89%), compared to those recruited through the community-provider (respectively 27%, 25%, 14%). GBM were more often repeat and recent HIVSS/ST-testers, and using pre-exposure prophylaxis (PrEP). Women and heterosexual men were more likely to buy an HIVSS/ST as part of a combination Sexually Transmitted Infections (STI) test package. Overall, main reasons for choosing HIVSS/ST were saving time (42%), anonymity (36%) and not having to talk to a GP (35%). Twenty-two percent of the study participants experienced some problems performing the HIVSS/ST, the most reported problem was obtaining sufficient blood through the finger prick (71%). Recommendations to improve accessibility of HIVSS/ST included more awareness (advertising by trustful providers), more access locations (pharmacies/supermarkets/schools) and lower costs. Our findings indicate that HIVSS/ST is a valuable additional HIV testing method for users, but more insight into the contribution of HIVSS/ST to HIV prevention policies is needed.
- 25 January 2025
- Published by Springer Nature in BMC Health Services Research
- Vol. 25 (1) , 1-11
Open AccessSelf-sampling and self-testing for HIV at a commercial and community-based test provider in the Netherlands: user preferences and usability
HIV self-sampling and -testing (HIVSS/ST) reduces testing barriers and potentially reaches populations who may not test otherwise. In the Netherlands, at-home HIV tests became commercially available around 2016, but data on user experiences are limited. This study aimed to explore characteristics of users and their experiences with HIVSS/ST. In 2022 and 2023, a survey was distributed among users of one online commercial provider and one community-based provider; either users ordered a commercial online HIVSS/ST or they sought a free-of-charge HIVST via the community-based provider. Questions included usability, preferences, and barriers of HIVSS/ST-testing. We compared characteristics and experiences of users between providers, risk groups and first-time and repeat testers. In total, 133 users completed the survey; 89 (67%) via the commercial provider and 44 (33%) via the community-based provider. Response rates per provider were 2% and 26%, respectively. Users who bought their test at the commercial provider were more often Gay and Bisexual Men (GBM) (42%), 35 + years (43%), and born in the Netherlands (89%), compared to those recruited through the community-provider (respectively 27%, 25%, 14%). GBM were more often repeat and recent HIVSS/ST-testers, and using pre-exposure prophylaxis (PrEP). Women and heterosexual men were more likely to buy an HIVSS/ST as part of a combination Sexually Transmitted Infections (STI) test package. Overall, main reasons for choosing HIVSS/ST were saving time (42%), anonymity (36%) and not having to talk to a GP (35%). Twenty-two percent of the study participants experienced some problems performing the HIVSS/ST, the most reported problem was obtaining sufficient blood through the finger prick (71%). Recommendations to improve accessibility of HIVSS/ST included more awareness (advertising by trustful providers), more access locations (pharmacies/supermarkets/schools) and lower costs. Our findings indicate that HIVSS/ST is a valuable additional HIV testing method for users, but more insight into the contribution of HIVSS/ST to HIV prevention policies is needed.
- Open Access
HIV and syphilis testing for women and heterosexual men aged above 25 years in the Netherlands: possibilities for targeted testing at sexual health centres
Objectives Targeted testing policy for HIV/syphilis at Dutch sexual health centres (SHCs) was evaluated for its efficiency in younger heterosexuals but not for heterosexuals ≥25 years. Currently, all older heterosexuals are tested for HIV/syphilis at SHCs. To explore possibilities for increased efficiency of testing in heterosexuals aged >25 years, this study aimed to identify determinants of HIV and syphilis diagnoses that could be used in targeted testing strategies. Design An observational study using surveillance data from all Dutch SHC. Participants Women and heterosexual men aged >25 years visiting SHC between 2015 and 2021. Primary and secondary outcome measures The primary outcome was HIV/syphilis diagnosis, determinants of a diagnosis were analysed. Based on these determinants and their applicability in SHC practice, different targeted testing scenarios were evaluated. For each scenario, the percentage of consultations involving HIV and syphilis testing and the total amount of missed HIV and syphilis diagnoses were calculated. Results 109 122 consultations were included among 75 718 individuals. The strongest determinants of HIV/syphilis diagnosis were HIV/syphilis-specific symptoms (adjusted OR (aOR) 34.9 (24.1–50.2)) and receiving partner notification (aOR 18.3 (13.2–25.2)), followed by low/middle education level (aOR 2.8 (2.0–4.0)), male sex (aOR 2.2 (1.6–3.0)) and age ≥30 years (aOR 1.8 (1.3–2.5)). When applying feasible determinants to targeted testing scenarios, HIV/syphilis testing would have been conducted in 54.5% of all consultations, missing 2 HIV and 3 syphilis diagnoses annually (13.4% and 11.4% of all diagnoses, respectively). In the scenario with the lowest number of missed HIV/syphilis diagnoses (0.3 HIV and 2 syphilis diagnoses annually), HIV/syphilis testing would have been conducted in 74.2% of all consultations. Conclusions In any targeted testing scenario studied, HIV and/or syphilis diagnoses would have been missed. This raises the question whether it is acceptable to put any of these scenarios into practice. This study contributes to a discussion about the impact of targeted testing policy.
Open AccessHIV and syphilis testing for women and heterosexual men aged above 25 years in the Netherlands: possibilities for targeted testing at sexual health centres
Objectives Targeted testing policy for HIV/syphilis at Dutch sexual health centres (SHCs) was evaluated for its efficiency in younger heterosexuals but not for heterosexuals ≥25 years. Currently, all older heterosexuals are tested for HIV/syphilis at SHCs. To explore possibilities for increased efficiency of testing in heterosexuals aged >25 years, this study aimed to identify determinants of HIV and syphilis diagnoses that could be used in targeted testing strategies. Design An observational study using surveillance data from all Dutch SHC. Participants Women and heterosexual men aged >25 years visiting SHC between 2015 and 2021. Primary and secondary outcome measures The primary outcome was HIV/syphilis diagnosis, determinants of a diagnosis were analysed. Based on these determinants and their applicability in SHC practice, different targeted testing scenarios were evaluated. For each scenario, the percentage of consultations involving HIV and syphilis testing and the total amount of missed HIV and syphilis diagnoses were calculated. Results 109 122 consultations were included among 75 718 individuals. The strongest determinants of HIV/syphilis diagnosis were HIV/syphilis-specific symptoms (adjusted OR (aOR) 34.9 (24.1–50.2)) and receiving partner notification (aOR 18.3 (13.2–25.2)), followed by low/middle education level (aOR 2.8 (2.0–4.0)), male sex (aOR 2.2 (1.6–3.0)) and age ≥30 years (aOR 1.8 (1.3–2.5)). When applying feasible determinants to targeted testing scenarios, HIV/syphilis testing would have been conducted in 54.5% of all consultations, missing 2 HIV and 3 syphilis diagnoses annually (13.4% and 11.4% of all diagnoses, respectively). In the scenario with the lowest number of missed HIV/syphilis diagnoses (0.3 HIV and 2 syphilis diagnoses annually), HIV/syphilis testing would have been conducted in 74.2% of all consultations. Conclusions In any targeted testing scenario studied, HIV and/or syphilis diagnoses would have been missed. This raises the question whether it is acceptable to put any of these scenarios into practice. This study contributes to a discussion about the impact of targeted testing policy.